Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus Target Price from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned an average recommendation of “Buy” from the thirteen ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $89.90.

Several analysts have recently weighed in on the stock. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, December 27th. Leerink Partners lifted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research report on Tuesday, December 3rd. Scotiabank increased their target price on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Finally, Stifel Nicolaus boosted their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd.

Insider Buying and Selling at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the completion of the transaction, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at $13,263,986.40. This trade represents a 8.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 108,334 shares of company stock valued at $6,070,020 in the last 90 days. 29.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of large investors have recently modified their holdings of the business. Amalgamated Bank raised its holdings in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new position in Janux Therapeutics in the second quarter valued at approximately $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the 4th quarter worth approximately $139,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Janux Therapeutics in the 2nd quarter valued at approximately $215,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Up 0.5 %

Shares of JANX opened at $40.91 on Wednesday. The company has a 50-day moving average price of $52.59 and a two-hundred day moving average price of $48.43. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -34.97 and a beta of 3.23. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. The company’s quarterly revenue was down 82.6% compared to the same quarter last year. Equities research analysts expect that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.